RIPK3 and cancer: These screen results were validated by testing 23 randomly selected cancer cell lines, which showed a complete resistance to TSZ- and TNFα+Cycloheximide+zVAD.fmk (TCZ)-induced necroptosis, lack of RIPK3 expression, and lack of MLKL Ser358 phosphorylation upon stimulation with TSZ treatment (Fig 2D and 2E and S2A Table).